

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



吉林省輝南長龍生化藥業股份有限公司

Jilin Province Huinan Changlong Bio-pharmacy Company Limited

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8049)

**(1) DELAY IN PUBLICATION OF AUDITED ANNUAL RESULTS
ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2019
AND DESPATCH OF ANNUAL REPORT
AND**

**(2) NOTICE OF BOARD OF DIRECTORS' MEETING
AND PUBLICATION OF UNAUDITED ANNUAL RESULTS
ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2019**

The board of directors (the “**Board**”) of Jilin Province Huinan Changlong Bio-pharmacy Company Limited (the “**Company**”), and together with its subsidiaries, collectively (the “**Group**”) hereby announces that, the auditors of the Company could not conduct the relevant audit field works in the People's Republic of China (the “**PRC**”) for the audit of the consolidated financial statements of the Group for the year ended 31 December 2019 under the current outbreak of novel coronavirus (COVID-19) epidemic (the “**Epidemic**”) that many provinces and municipalities in the PRC have implemented travel restrictions and border control measures and mandatory medical surveillance for 14 days for people arriving from areas with active community transmission of the Epidemic. This will inevitably cause delay in the publication and despatch of the audited annual results announcement and the annual report of the Group for the year ended 31 December 2019.

Should the relevant travel restriction measures in relation to the Epidemic in the PRC be relieved, it is expected that the audit field works of the auditors will be resumed as soon as practicable. The Company will publish and despatch the audited annual results announcement and the annual report for the year ended 31 December 2019 as soon as practicable. Further announcement(s) will be made as and when appropriate by the Company in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”).

However, in order to keep the shareholders of the Company and the public informed of the Group's business operation and financial position, the Board has decided to publish the unaudited annual results announcement of the Company for the year ended 31 December 2019 on 31 March 2020.

The board hereby announces that a meeting of the Board will be held at Economic Development Zone, Chaoyang Town, Huinan County, Tonghua, Jilin Province (吉林省通化市輝南縣朝陽鎮經濟開發區), the PRC on Tuesday, 31 March 2020 at 10:00 a.m. for the following purposes:

1. To consider and approve the unaudited consolidated financial statements for the year ended 31 December 2019 of the Company and its subsidiaries, and to approve the associated draft announcement and a summary of the unaudited final results thereof to be published on the GEM website;
2. To consider the payment of final dividend, if any;
3. To consider the closure of the Register of Members, if necessary; and
4. To transact any other business.

By order of the Board
Jilin Province Huinan Changlong Bio-pharmacy Company Limited
Zhang Hong
Chairman

Jilin Province, the PRC
19 March 2020

As at the date of this announcement, the Board comprises six executive directors, being Zhang Hong, Zhang Xiao Guang, Zhao Bao Gang, Wu Guo Wen, Zhang Yi and Xu Xiang Fu; and three independent non-executive directors, being Gao Yong Cai, Gao Qi Pin and Tian Jie.

This announcement, for which the directors of Jilin Province Huinan Changlong Bio-pharmacy Company Limited collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to Jilin Province Huinan Changlong Bio-pharmacy Company Limited. The directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the "Latest Company Announcements" page on the GEM Website at www.hkgem.com for at least 7 days from the date of its posting.